A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

191 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-15

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate the treatment preferences of patients with Neuroendocrine Tumors (NETS) and nurses who are involved in the care of individuals with NETs. NETs are a type of abnormal growth that can develop in various parts of the body, such as the lungs, pancreas, gastrointestinal tract, or other organs.

NETs originate from specialized cells called neuroendocrine cells, which are responsible for producing hormones in our bodies.

The study focuses on hypothetical preferences regarding the use of two different type of devices for administering Somatostatin analogues (SSAs), which could be used in the treatment of NETs.

SSAs work by imitating the actions of a hormone called somatostatin that naturally exists in our bodies. These treatment help to control the symptoms of NETs by blocking the release of hormones from the tumor cells.

The devices under consideration are a motorized injector versus a manual injector.

Participants in the study will be asked to take part in:

1. An interview based on a draft survey: 60-minute interview over videocall, to examine participants understanding of the online survey; or
2. Final online survey: 30-minute online survey. This involves presenting patients and nurses with different treatment options and asking them to choose their preferred option.

By analysing the choices made by participants, researchers can understand which attributes of the injector devices are most important to patients and nurses.

Individual participation is limited to the interview based on a draft survey (60 minutes) or the final online survey (30 minutes).

No further participation is required beyond this.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Cryoablation for Metastatic Lung Tumors

NCT01957787

Neoplasm Metastasis

COMPLETED NA

Early-Phase Safety of Proton Therapy Equipment

NCT02315989

Malignant Glioma Hepatocellular Carcinoma Head and Neck Malignant Tumor +1 more

COMPLETED NA

Neuroendocrine Tumors - Patient Reported Outcomes

NCT05064150

Neuroendocrine Tumors Gastroenteropancreatic Neuroendocrine Tumor Lung Neuroendocrine Neoplasm +1 more

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

NCT02683941

Neuroendocrine Tumors in Lung

TERMINATED PHASE3

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

NCT03112694

Neuroendocrine Tumors

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroendocrine Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients (cognitive interviews)

* Aged 18 years or over
* Reside in the US or Canada
* Have been diagnosed with NETs by a healthcare professional (based on self-report and confirmed via data quality checks)
* Have any SSA treatment experience in the past 2 years
* Be fluent in spoken and written English
* Have read, understood, and consented to participate in the study
* Be able to complete the survey on a standard-sized tablet device (minimum 10 inches), laptop, or desktop computer
* Be able and willing to screenshare with the interviewer

Patients (online survey and DCE)

* Aged 18 years or over
* Reside in the US or Canada
* Have been diagnosed with NETs by a healthcare professional (based on self-report and confirmed via data quality checks)
* Have any SSA treatment experience in the past 2 years
* Be fluent in spoken and written English
* Have read, understood, and consented to participate in the study
* Be able to complete the survey on a standard-sized tablet device (minimum 10 inches), laptop, or desktop computer
* Have not participated in the cognitive interviews

Nurses (cognitive interviews)

* Reside in the US or Canada
* Nurse with at least 12 months experience caring for patients with NETs
* Have administered at least one long-acting SSA injection to a patient with NETs in the past 12 months
* Be fluent in spoken and written English
* Have read, understood, and consented to participate in the study
* Be able to complete the survey on a standard-sized tablet device (minimum 10 inches), laptop, or desktop computer
* Be able and willing to screenshare with the interviewer

Nurses (online survey and DCE)

* Reside in the US or Canada
* Nurse with at least 12 months experience caring for patients with NETs
* Have administered at least one long-acting SSA injection to a patient with NETs in the past 12 months
* Be fluent in spoken and written English or Canadian French
* Have read, understood, and consented to participate in the study
* Be able to complete the survey on a standard-sized tablet device (minimum 10 inches), laptop, or desktop computer
* Have not participated in the cognitive interviews